OPK at a glance
OPKO HEALTH, INC. (OPK, SEC CIK 944809) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), OPKO HEALTH, INC. (OPK) reported revenue of $606.9 million (down 14.9% from FY2024) and a net loss of $225.7 million. Diluted EPS was -$0.30.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding OPKO HEALTH, INC. (OPK) shares worth $163.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by PAGANELLI JOHN A on November 5, 2026 of 9,175 shares at $1.82 per share.
- In the last 90 days, OPK insiders reported 0 open-market purchases ($0) and 2 open-market sales ($25K) on Form 4, a net sale of $25K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $606.9M
- −14.9% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$25K
- 13F holders
- 29 funds
- $163.6M · +2 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $65.4M, up 16% YoY from $56.4M, driven by Eli Lilly royalties and Rayaldee sales
- Operating loss $31.4M vs $33.6M YoY, equivalent margins of -48.0% vs -59.5%
- Best segment Global Products: revenue $48.4M, operating income $6.0M vs loss $1.2M
- Worst segment Innovative Biotech: operating loss $26.8M vs $22.5M, R&D $30.4M vs $26.3M
- Cash, equivalents and restricted cash $403.2M; operating cash use $99.1M and royalty-note proceeds $123.1M YTD
- Outlook: liquidity expected sufficient beyond 12 months, with risks from pipeline spending, clinical milestones, financing needs and tariffs
Risk Factors
- No material changes to risk factors from the most recent Form 10-K
- Key carried-forward risks remain those disclosed in the Form 10-K, without quarterly updates
AI summary of the OPK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers OPKO’s Q3 2026 operating and financial results for the quarter ended September 30, 2026
- Conference call scheduled for business updates, financial results discussion and financial guidance
Item EX-99.1: Item EX-99.1
- Q3 continuing-operations revenue $65.4M, up 16%, while net loss widened to $35.5M, or $0.05 per share
- Labcorp deal offers $722M upfront plus up to $150M tied to 4Kscore sales, pending approvals and closing conditions
Item 1.01: Entry into a Material Definitive Agreement
- OPKO agreed to sell BioReference testing assets to Labcorp for $722 million cash at closing
- Additional consideration up to $150 million over 10 years tied to 4Kscore prostate test revenue
Item 8.01: Other Events
- $121 million of 3.75% convertible notes became convertible through December 31, 2026
- Conversion triggered after OPKO shares exceeded $1.495, or 130% of the $1.15 conversion price
AI summaries of OPK 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for OPK
Don't miss the next OPK filing
- Alerts as it files. A push when OPK files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut OPK, by share count.
- Ask anything. An AI agent that reads every OPK filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| PAGANELLI JOHN A | Sell | Nov 5, 2026 | 9,175 | $1.82 |
| PAGANELLI JOHN A | Sell | Nov 5, 2026 | 4,426 | $1.78 |
| Logal Adam | F | Jul 24, 2026 | 53,266 | $1.22 |
| Rubin Steven D | F | Jul 24, 2026 | 53,266 | $1.22 |
| PAGANELLI JOHN A | A | Jun 18, 2026 | 30,000 | - |
| Lachman Prem A | A | Jun 18, 2026 | 30,000 | - |
| UPPALURI SUBBARAO V | A | Jun 18, 2026 | 80,000 | - |
| PFENNIGER RICHARD C JR | A | Jun 18, 2026 | 60,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $713.1M | $606.9M |
| Gross Profit | $318.1M | $218.5M | $205.9M |
| Operating Income | - | -$152.1M | -$117.4M |
| Net Income | -$188.9M | -$53.2M | -$225.7M |
| Gross Margin | - | 30.6% | 33.9% |
| Op. Margin | - | -21.3% | -19.3% |
| Net Margin | - | -7.5% | -37.2% |
| Balance Sheet | |||
| Total Assets | $2.0B | $2.2B | $1.9B |
| Equity | - | $1.4B | $1.3B |
| ROE | - | -3.9% | -17.8% |
| Per Share | |||
| EPS | - | $-0.08 | $-0.30 |
| Cash Flow | |||
| Operating CF | -$28.2M | -$183.5M | -$178.5M |
Source: XBRL data in OPKO HEALTH, INC. (OPK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate OPK share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $163.6M |
| Q2 2026 | 27 | $147.8M |
| Q1 2026 | 27 | $110.5M |
| Q4 2025 | 28 | $124.3M |
| Q3 2025 | 27 | $152.9M |
| Q2 2025 | 27 | $130.7M |
| Q1 2025 | 25 | $130.3M |
| Q4 2024 | 22 | $87.1M |
- Citadel Advisors LLC+1.35M (+95%)
- Goldman Sachs Group+969.8K (+14%)
- JPMorgan Chase & Co+644.5K (+383%)
- Two Sigma Investments+519.1K (+295%)
- State Street Corp+343.6K (+3%)
- AQR Capital Management−937.7K (-76%)
- Vanguard Portfolio Management LLC−279.8K (-2%)
- Wells Fargo & Co−274.6K (-78%)
- BlackRock−157.6K (-0%)
- Vanguard Capital Management LLC−135.7K (-1%)
- Renaissance Technologies LLC+1.01M
- StoneX Group Inc.+30.3K
- Principal Financial Group+20.3K
- FMR LLC (Fidelity)−15.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 212 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
OPK filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 5, 2026 | - | - | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Oct 15, 2026 | - | Analysis | - |
| 8-K | Oct 2, 2026 | - | Analysis | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| SC 13D | Aug 7, 2026 | - | - | |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 10-Q | Jul 27, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 27, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 10-Q | Apr 28, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 28, 2026 | - | Analysis | - |
| 4 | Mar 20, 2026 | - | - | - |
| 4 | Mar 20, 2026 | - | - | - |
| 8-K | Mar 19, 2026 | - | Analysis | - |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 26, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
OPK SEC filings: frequently asked questions
Are OPK insiders buying or selling?
In the last 90 days, OPKO HEALTH, INC. (OPK) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $24,577 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold OPK stock?
As of September 30, 2026, the largest OPKO HEALTH, INC. (OPK) holders among the 13F filers tracked by SignalX were BlackRock ($59.3 million), Vanguard Capital Management LLC ($23.9 million), Vanguard Portfolio Management LLC ($23.6 million), State Street Corp ($17.2 million), Goldman Sachs Group ($12.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was OPK's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), OPKO HEALTH, INC. (OPK) reported revenue of $606.9 million (down 14.9% from FY2024) and a net loss of $225.7 million. Diluted EPS was -$0.30. The figures come from the XBRL data in the 10-K.
What did OPK report in its latest 8-K?
OPKO HEALTH, INC. (OPK) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers OPKO’s Q3 2026 operating and financial results for the quarter ended September 30, 2026.
What are the latest OPK SEC filings?
OPKO HEALTH, INC. (OPK) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 5, 2026.
What is OPK's SEC CIK number?
OPKO HEALTH, INC. (OPK)'s SEC Central Index Key (CIK) is 944809. EDGAR lists every OPK filing under that number.
Ask anything about OPK
The research agent reads OPK's filings, financials, insider trades and 13F holders, then answers with sources.